The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
5 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,198,065 in first-year total cost, median $299,999.
Most frequent study sections
- Special Emphasis Panel[ZRG1 MOSS-D (10)]4
- Special Emphasis Panel[ZRG1 SBIB-Y (11)]1
Most frequent institutions
- APEX ORTHOPAEDIC TECHNOLOGIES LLC1
- ARAVIS BIOTECH, LLC1
- FORSAGEN LLC1
- REELIN THERAPEUTICS, INC.1
- XLOCK BIOSCIENCES, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Targeting the CCR6-CCL20 pathway for treatment of psoriatic joint and entheseal inflammation1R44AR081754-01A1 | CLARKE, WILLIAM RVOLKMAN, BRIAN F | XLOCK BIOSCIENCES, LLC, WI | $998,606 | ZRG1 |
| 2022 | A novel role for Reelin therapeutics in rheumatoid arthritis1R43AR081762-01 | KOUNNAS, MARIA Z | REELIN THERAPEUTICS, INC., CA | $300,000 | ZRG1 |
| 2022 | X-ray Visualized Implanted Sensor for Prosthetic Joint Infection (X-VIS-PJI)1R43AR081748-01 | ANKER, JEFFREY NCALCUTT, LINDSEY SANDERS | ARAVIS BIOTECH, LLC, SC | $299,999 | ZRG1 |
| 2022 | R-FIX (Rib-FIXation System) for Severe Progressive Spinal Deformity1R43AR080507-01A1 | GROSS, RICHARD H.YAO, HAI | APEX ORTHOPAEDIC TECHNOLOGIES LLC, SC | $299,886 | ZRG1 |
| 2021 | A BioAdhesive to Localize and Direct Stem Cells to Treat Damaged Cartilage1R43AR080528-01 | TSINMAN, ANTONINA | FORSAGEN LLC, PA | $299,574 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.